Developing research facilities and the Regenerative-Inducing Medicine Collaborative Research Institute
First written in FY2019. 9 of 13 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2026.
60 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Capital expenditure during the fiscal year amounted to ¥7.632 million. The main expenditure was for the purchase of PCs and office automation equipment.」
The Company invested ¥7.632 million in capital expenditure for its research and development facilities, primarily in PCs and office automation equipment. - FY2025AdvancedAnnual report
「Capital expenditure during the fiscal year was ¥44.175 million. The principal investment was construction work for a constant-temperature room.」
The company made ¥44.175 million in capital investments in its research and development base, primarily for construction of a constant-temperature room. - FY2024RestatedAnnual report
「The company makes capital investments after comprehensively considering research progress, investment efficiency and other factors.」
The policy of making research facility investments based on research progress and investment efficiency has been reaffirmed. - FY2022RestatedAnnual report
「The company makes capital investments after comprehensively considering research progress, investment efficiency and other factors.」
The policy of making research facility investments based on research progress and investment efficiency has been reaffirmed. - FY2022-Q2AdvancedAnnual report
「By securing on a lease the Collaborative Research Institute, which enables closer collaboration with Osaka University, the company's joint research partner, on the sixth and seventh floors of the Techno Alliance Building at Osaka University's Suita Campus (1,540㎡), the company substantially reduced establishment costs compared with its initial assumptions and brought forward by approximately 2 years the establishment of its planned development base for regenerative induction medicine. ... The company also secured a 339㎡ animal testing facility, expanding its floor area by 223㎡ from the existing facility.」
The company secured a 1,540㎡ Collaborative Research Institute at Osaka University on a lease and brought forward the establishment of its development base by approximately 2 years. The animal testing facility was also expanded by 223㎡ from the existing facility, bringing the secured floor area to 339㎡. - FY2021-Q3RestatedAnnual report
「In addition, in January 2021, the company expanded its head-office research institute and newly established an animal testing facility of approximately 223㎡ within the same building. The facility is used for screening new drug candidates and efficacy testing using laboratory animals, and is expected to contribute to further expanding the disease areas targeted by regenerative induction medicine.」
The expansion of the head-office research institute and establishment of an approximately 223㎡ animal testing facility in January 2021, as well as its intended uses, have been reaffirmed. - FY2021-Q2AdvancedAnnual report
「In addition, in January 2021, the company expanded its head-office research institute and newly established an animal testing facility of approximately 223㎡ within the same building. The facility is planned to be used for screening new drug candidates, efficacy testing using laboratory animals, and testing of devices for concentrating stem cells in vivo. Completion of the facility is expected to significantly improve the efficiency of nonclinical research in regenerative induction medicine and contribute to further expanding the disease areas targeted by regenerative induction medicine.」
In January 2021, the company expanded its head-office research institute and newly established an approximately 223㎡ animal testing facility. The facility is planned to improve the efficiency of nonclinical research and support expansion into additional disease areas. - FY2020AdvancedAnnual report
「Capital expenditure during the fiscal year was ¥226.721 million. The principal investment was the establishment, jointly with Osaka University, a national university corporation, of the Regenerative Induction Medicine Collaborative Research Institute (floor area: 1,540㎡) as the company's new research and development base, which will lead the world in regenerative induction medicine research. In addition to the investment recorded as property, plant and equipment in connection with the opening of the institute, the company invested ¥479.281 million in research equipment to strengthen its research and development structure.」
The company opened a 1,540㎡ collaborative research institute and invested ¥226.72 million in capital expenditure and ¥479.28 million in research equipment to strengthen its research and development structure. - FY2020-Q3AdvancedAnnual report
「In addition, the company established the Regenerative Induction Medicine Collaborative Research Institute in June 2020 within an existing facility on the Osaka University campus. With a floor area of 1,540㎡, the institute provides a new research base capable of supporting the company's expanding research operations, which are its most important management priority in achieving its medium- to long-term growth strategy.」
The plan progressed from the initial establishment and agreement stages to securing a 1,540㎡ collaborative research institute and opening it in June 2020. - FY2020-Q2AdvancedAnnual report
「The Collaborative Research Institute will be established for a period of 10 years, from 1 April 2020 to 31 March 2030. ③ Under the agreement, the company will bear total research expenses of approximately ¥2.1 billion over the 10-year establishment period.」
The Regenerative Induction Medicine Collaborative Research Institute with Osaka University progressed from the planning stage to a resolution on its joint establishment and the formalization of the agreement. The institute has a floor area of 1,540㎡, with opening scheduled from April 2020, and the company is to bear approximately ¥2.1 billion in research expenses over 10 years. - FY2019First statedAnnual report
「Going forward, the company plans to establish a research structure based on two pillars: a research institute conducting nonclinical and preclinical research, primarily at animal testing facilities, and a Regenerative Induction Medicine Research Institute conducting clinical research and supporting clinical trials.」
The company plans to establish two research pillars: a research institute centered on animal testing facilities and a research institute supporting clinical research and clinical trials. It also indicated that, due to the reduced amount raised at the time of listing, the facilities are planned to be established in leased rather than company-owned properties.